US4959353A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Promotion of corneal stroma wound healing with human epidermal growth factor prepared from recombinant DNA
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1987-04-23
•
Granted: 1990-09-25
•
Expires: 2007-04-23
Abstract
Abstract A method for treating corneal stromal wounds to promote regeneration of the affected tissue is provided. This method employs recombinant human epidermal growth factor.
Inventors
- 👤 Gregory L. Brown
- 👤 Richard Eiferman
- 👤 Gregory L. Schultz
- 👤 Pablo D. T. Valenzuela
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:15
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/485; A; A61; A61P; A61P17/00; A61P27/00; A61P27/02; A61P43/00; A61K; A61K38/00
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
61 words
A method for treating corneal stromal wounds to promote healing, said method comprising applying human epidermal growth factor (hEGF) to the wound, where said hEGF is produced by expressing an hEGF gene encoding a polypeptide having at least substantially the same amino acid sequence and the same corneal stromal wound-healing activity as naturally occurring human epidermal growth factor in a microorganism.
Claim 2
Independent Claim
61 words
A method for treating corneal stromal wounds to promote healing, said method comprising applying human epidermal growth factor (hEGF) to the wound, where said hEGF is produced by expressing an hEGF gene encoding a polypeptide having at least substantially the same amino acid sequence and the same corneal stromal wound-healing activity as naturally occurring human epidermal growth factor in a microorganism.
Claim 3
Dependent Claim
13 words
A method as in claim 1, wherein the hEGF is produced in yeast.
Claim 4
Dependent Claim
38 words
A method as in claim 2, wherein the yeast is transformed with a DNA construct carrying a hEGF gene under the transcriptional and translational control of regulatory sequences including secretory leader and processing signal sequences functional in yeast.
Claim 5
Dependent Claim
23 words
A method as in claim 1, wherein the hEGF is present in a physiologically acceptable carrier at from 1 μg/ml to 10 μg/ml.
Claim 6
Dependent Claim
20 words
A method as in claim 1 wherein the hEGF is applied continually to the wound over an extended time period.
Claim 7
Dependent Claim
18 words
A method as in claim 5 wherein the continual application is achieved via a sustained release dosage form.
Claim 8
Dependent Claim
14 words
A method as in claim 6 wherein the sustained release dosage form is liposomes.
Claim 9
Dependent Claim
12 words
A method as in claim 7 wherein the liposomes are multilamellar liposomes.
Claim 10
Dependent Claim
20 words
A method as in claim 5 wherein the sustained release dosage form comprises the hEGF incorporated into a semipermeable polymer.
Claim 11
Dependent Claim
14 words
A method as in claim 9 wherein the semipermeable polymer is ethylene-vinyl acetate copolymer.
Claim 12
Dependent Claim
18 words
A method as in claim 5 wherein the continual application is achieved via a multiplicity of intermittent doses.
Claim 13
Independent Claim
106 words
A method for treating corneal stromal wounds to promote healing, said method comprising applying to the wound a polypeptide capable of stimulating the proliferation of epithelial and stromal cells, where said polypeptide is produced by growing, in a culture medium suitable for growth of yeast, a yeast host which has been transformed by an extrachromosomal element carrying a gene encoding a polypeptide having at least substantially the same amino acid sequence and the same corneal stromal wound-healing activity as naturally occurring human epidermal growth factor under the transcriptional and translational control of regulatory sequences including secretory leader and processing signal sequences functional in said yeast host.
Claim 14
Independent Claim
106 words
A method for treating corneal stromal wounds to promote healing, said method comprising applying to the wound a polypeptide capable of stimulating the proliferation of epithelial and stromal cells, where said polypeptide is produced by growing, in a culture medium suitable for growth of yeast, a yeast host which has been transformed by an extrachromosomal element carrying a gene encoding a polypeptide having at least substantially the same amino acid sequence and the same corneal stromal wound-healing activity as naturally occurring human epidermal growth factor under the transcriptional and translational control of regulatory sequences including secretory leader and processing signal sequences functional in said yeast host.
Claim 15
Dependent Claim
16 words
A method as in claim 12, wherein the hEGF gene is composed of preferred yeast codons.
Claim 16
Dependent Claim
23 words
A method as in claim 12, wherein the polypeptide is present in a physiologically acceptable carrier at from 1 μg/ml to 10 μg/ml.
Claim 17
Dependent Claim
20 words
A method as in claim 12 wherein the hEGF is applied continually to the wound over an extended time period.
Claim 18
Dependent Claim
18 words
A method as in claim 15 wherein the continual application is achieved via a sustained release dosage form.
Claim 19
Dependent Claim
14 words
A method as in claim 16 wherein the sustained release dosage form is liposomes.
Claim 20
Dependent Claim
12 words
A method as in claim 18 wherein the liposomes are multilamellar liposomes.
Claim 21
Dependent Claim
20 words
A method as in claim 16 wherein the sustained release dosage form comprises the hEGF incorporated into a semipermeable polymer.
Claim 22
Dependent Claim
14 words
A method as in claim 20 wherein the semipermeable polymer is ethylene-vinyl acetate copolymer.
Claim 23
Dependent Claim
18 words
A method as in claim 15 wherein the continual application is achieved via a multiplicity of intermittent doses.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-24 | 1994-03-26 | 1994-09-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-24 | 1998-03-26 | 1998-09-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-24 | 2002-03-26 | 2002-09-25 | $7700.00 | Window Closed / Lapsed |